Skip to main content

Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines

CBE ID
1855
1.4 Project
Cancer
Endorsed
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
E&M Cycle
Fall 2018
Is Under Review
No
1.3 Measure Description

Percentage of patients with quantitative breast tumor HER2 IHC evaluation using the ASCO/CAP recommended manual system or a computer-assisted system consistent with the optimal algorithm for HER2 testing as described in the current ASCO/CAP guidelines.

    • 1.14 Numerator

      Breast cancer patients receiving quantitative breast tumor HER2 IHC evaluation using the ASCO/CAP recommended manual system or a computer-assisted system consistent with the optimal algorithm for HER2 testing as described in the ASCO/CAP guideline *

    • 1.15 Denominator

      All breast cancer patients with quantitative breast tumor evaluation by HER2 IHC

      ICD-10 diagnosis codes for breast cancer: C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929

      AND

      CPT codes: Quantitative IHC Evaluation – 88360 or 88361 (The CPT descriptor for 88360 and 88361 is, “Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semi-quantitative, each antibody.”)

    • Exclusions

      None

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Fall Cycle 2018
      Initial Endorsement
      Last Updated
      Removal Date